Pretransplant lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after liver transplantation

Liver Transplantation

Volumn 20, Issue 12, 2014, Pages 1497-1507

  Nierenberg, Natalie E ^a   Poutsiaka, Debra D ^a   Chow, Jennifer K ^a   Cooper, Jeffrey ^a   Price, Lori Lyn ^b   Freeman, Richard B ^c   Rohrer, Richard ^a   Snydman, David R ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c DARTMOUTH COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; END STAGE LIVER DISEASE; EPSTEIN BARR VIRUS INFECTION; FEMALE; GLOMERULUS FILTRATION RATE; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; INFLUENZA A; INFLUENZA B; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MYCOSIS; NOROVIRUS INFECTION; PARAINFLUENZA VIRUS INFECTION; PARVOVIRUS INFECTION; POSTOPERATIVE INFECTION; PREOPERATIVE COMPLICATION; PRETRANSPLANT LYMPHOPENIA; PROGNOSIS; RETRANSPLANTATION; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; VIRUS INFECTION; ADVERSE EFFECTS; COMPLICATION; CYTOMEGALOVIRUS; LIVER FAILURE; LYMPHOCYTE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; VIROLOGY;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; LYMPHOCYTES; LYMPHOPENIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VIRUS DISEASES;

EID: 84912066431     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23991     Document Type: Article

References (31)

1. Blair JE, Kusne S,. Bacterial, mycobacterial, and protozoal infections after liver transplantation-part 1. Liver Transpl 2005; 11: 1452-1459.
2. Fishman JA, Rubin RH,. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751.
3. Bodey G,. The changing face of febrile neutropenia from monotherapy to moulds to mucositis. Fever and neutropenia: the early years. J Antimicrob Chemother 2009; 63 (suppl 1): i3-i13.
4. +adenosine triphosphate activity. Clin Dev Immunol 2013; 2013: 982163.
5. +alphabeta T cells responding to human cytomegalovirus infection in kidney transplant recipients. J Infect Dis 2009; 200: 1415-1424.
6. Egli A, Humar A, Kumar D,. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 2012; 55: 1678-1689.
7. +T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203: 1474-1483.
8. Schreibman T, Friedland G,. Use of total lymphocyte count for monitoring response to antiretroviral therapy. Clin Infect Dis 2004; 38: 257-262.
9. Yu P, Fu YX,. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 2006; 86: 231-245.
10. Siddiqui M, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 2006; 134: 596-601.
11. Nagai S, Abouljoud MS, Kazimi M, Brown KA, Moonka D, Yoshida A,. Peritransplant lymphopenia is a novel prognostic factor in recurrence of hepatocellular carcinoma after liver transplantation. Transplantation 2014; 97: 694-701.
12. Fernández-Ruiz M, López-Medrano F, Romo EM, Allende LM, Meneu JC, Fundora-Suarez Y, et al. Pretransplant lymphocyte count predicts the incidence of infection during the first two years after liver transplantation. Liver Transpl 2009; 15: 1209-1216.
13. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008; 3: 1526-1533.
14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al.; for CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
15. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al.; for Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir versus oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
16. UNOS. MELD/PELD calculator documentation. http://www.unos.org/docs/MELD-PELD-Calculator-Documentation.pdf. Accessed May 2009.
17. Munoz-Price LS, Slifkin M, Ruthazer R, Poutsiaka DD, Hadley S, Freeman R, et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004; 39: 1293-1299.
18. Paya CV, Smith TF, Ludwig J, Hermans PE,. Rapid shell vial culture and tissue histology compared with serology for the rapid diagnosis of cytomegalovirus infection in liver transplantation. Mayo Clin Proc 1989; 64: 670-675.
19. Mazzulli T, Drew LW, Yen-Lieberman B, Jekic-McMullen D, Kohn DJ, Isada C, et al. Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia. J Clin Microbiol 1999; 37: 958-963.
20. Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK,; for American Society of Transplantation Infectious Diseases Community of Practice and Canadian Society of Transplantation. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009; 9: 258-268.
21. Ljungman P, Griffiths P, Paya C,. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
22. Arbo MD, Snydman DR,. Influence of blood culture results on antibiotic choice in the treatment of bacteremia. Arch Intern Med 1994; 154: 2641-2645.
23. George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, Rubin RH,. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103: 106-113.
24. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-790.
25. Remington RD, Schork MA,. Statistics With Applications to the Biological and Health Sciences. Englewood Cliffs, NJ: Prentice-Hall; 1970.
26. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
27. Allison PD,. Survival Analysis Using SAS: A Practical Guide Estimating Cox Regression Models With PROC PHREG. Cary, NC: SAS Institute; 1995.
28. Cox DR,. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
29. Shetland ES, Kleinman K, Chain EM,. Model building in PROC PHREG with automatic variable selection and information criteria [paper 206-230]. In: SUGI '30 Proceedings (Philadelphia). Cary, NC: SAS Institute; 2005. http://www2.sas.com/proceedings/sugi30/206-30.pdf.
30. Iida T, Kaido T, Yagi S, Yoshizawa A, Hata K, Mizumoto M, et al. Posttransplant bacteremia in adult living donor liver transplant recipients. Liver Transpl 2010; 16: 1379-1385.
31. Gerna G, Lilleri D, Chiesa A, Zelini P, Furione M, Comolli G, et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant 2011; 11: 2463-2471.